YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

136 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 447 In stock
USD 770 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 136 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxNVczKGh? M{GwbGROW09? MXHJR|UxRTBwMEC5JOKyKDBwMECwPUDPxE1? NXjw[W55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e M3nnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXaO2U4OiCq MlvuSG1UVw>? M{\qRmlEPTB;MD6wOFAhyrFiMD6wNVMh|ryP M4\DRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 NH\QWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu3NkBp MnHsSG1UVw>? MUXJR|UxRTBwMEWxJOKyKDBwMEGzJO69VQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
CMK M2HM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:3NkBp MWLEUXNQ MUPJR|UxRTBwMEWzJOKyKDBwMEC5JO69VQ>? M2\zS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
MV4-11 M1rzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\IfFczKGh? NEDpe4NFVVOR NGPUV3NKSzVyPUCuNFU2KMLzIECuNFI5KM7:TR?= NXzBe|Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
AML-193 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XCeVczKGh? MYPEUXNQ NHTRdFRKSzVyPUCuOFYzKMLzIECuNFYxKM7:TR?= NELGV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12wdFczKGh? MlrlSG1UVw>? NXfLW3BWUUN3ME2wMlAxOSEEsTCwMlAxODJizszN NFe1b5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
ML-2 NWW5cXNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zO|IhcA>? MnLHSG1UVw>? NXHrRlZHUUN3ME2wMlAxQSEEsTCwMlAxOiEQvF2= NEi2S2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
OCI/AML3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq3NkBp NIryR29FVVOR MormTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
HEL NWOweYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\aZYI4OiCq MmXqSG1UVw>? MY\JR|UxRTBwNUW5JOKyKDBwMEO4JO69VQ>? NFToT3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
ME-1 NWrRWlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqeFl7PzJiaB?= MUPEUXNQ NYLsVG42UUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= MnHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
THP-1 NIr6Z2JCeG:ydH;zbZMhSXO|YYm= NWrncm8{OcLizszN NImxdHA4OiCq MlTmSG1UVw>? MnHzbY5lfWOnczDhdI9xfG:|aYO= M1nkbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
M-07e M1:ye2Z2dmO2aX;uJGF{e2G7 MXyw5qCUOcLizszN M4rEVFczKGh? NX7mbYhMTE2VTx?= NVnkdnNNcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NWTve4VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
THP-1 M2LwNmZ2dmO2aX;uJGF{e2G7 NHrn[lgx6oDVMdMg{txO NFHXdG84OiCq M{TVPWROW09? NWXZc|NlcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> M{LQTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
CMK NVz4[4tzTnWwY4Tpc44hSXO|YYm= M4LUXFDjiJNzwrFOwG0> MmfkO|IhcA>? M1\m[2ROW09? M1LrcIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NEHzNWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
AML-193 NGezS2FHfW6ldHnvckBCe3OjeR?= NGHvbHkx6oDVMdMg{txO M3rEUFczKGh? NIHxOWFFVVOR NGW4fWtqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
Kasumi-1 NXfPTJJnTnWwY4Tpc44hSXO|YYm= M2PIeFDjiJNzwrFOwG0> NEPoe5E4OiCq MlnKSG1UVw>? NXjvb2t5cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MmHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
MV4-11 M2DBV2Z2dmO2aX;uJGF{e2G7 NGP0T3cx6oDVMdMg{txO NGnlRXg4OiCq NFfNOodFVVOR MWjpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
MUG-Chor  NVr3b3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\KNmcxNTVizszN M1LCelI1NzR6IHi= MnzBTWM2OD15LkC15qCKdk1iZn;yJFQ5cA>? NYexeoJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
U-CH1  NVPZUGR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXywMVUh|ryP NVPTcnpqOjRxNEigbC=> NYjqbYh2UUN3ME25MlA{6oDLbl2g[o9zKDR6aB?= NYPrfXFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
KATOIII MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXMNmgyOC9{MDDuUS=> MlrTOFghcA>? NXXOfVM1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3fKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO1NFU2Lz5{NU[zOVA2PTxxYU6=
AGS  MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L1e|ExNzJyIH7N Mk\DOFghcA>? NXOxN5JFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2jqRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO1NFU2Lz5{NU[zOVA2PTxxYU6=
SACC-83 NUXEOXNETnWwY4Tpc44hSXO|YYm= MmnEOUBvVQ>? Mlm1OFghcA>? NIfpd2tl\WO{ZXHz[ZMhdnWlbHXhdkBmgHC{ZYPzbY9vKG:oIFjJSk0y|rF? NVTRSYZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFU3OzVpPkK1OFg2PjN3PD;hQi=>
INA-6 NF;1WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTUfotoOC13MECgcm0> MmLHOFghcA>? MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
U-266 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMVUxOCCwTR?= M2fJTFQ5KGh? Mn\QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUfIeFgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
MOLP-8 NHS1eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMVUxOCCwTR?= NX;pc4RVPDhiaB?= NGfPfGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
HG-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKwMVUxOCCwTR?= M1;oU|Q5KGh? M{L1dIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
NCI-H929 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrxOZpmOC13MECgcm0> NF3ySZQ1QCCq Ml2zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWnXSpB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
OPM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPNXGgxNTVyMDDuUS=> NUfaUoNPPDhiaB?= NYnJWmJ2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF72ZZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
L-363 M3PMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMVUxOCCwTR?= MnnrOFghcA>? M4DudYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1LvRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
MOLP-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmwMVUxOCCwTR?= MV60PEBp MoLubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUjmdZpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
KMS-12-BM NFHCcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojwNE02ODBibl2= NHTkSIw1QCCq NULFbFk6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3j4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
SK-MM-2 NYXKd4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTYfllwOC13MECgcm0> NEPoe4I1QCCq NInJZWFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mmm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
U-266 M2rifmFxd3C2b4Ppd{BCe3OjeR?= MVSwMVUxKG6P NUDjT|Z4OjRiaB?= NF:5SnRqdmS3Y3XzJIFxd3C2b4Ppdy=> MoWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
INA-6  NVvJTmxjSXCxcITvd4l{KEG|c3H5 M4fnUFAuPTBibl2= NGexUWMzPCCq MUTpcoR2[2W|IHHwc5B1d3Orcx?= NHjtSHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
MCF7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu3NkBp NHvx[HRKSzVyPUGzJOKyKDZibl2= NWT3copwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamR6 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXVO|IhcA>? MmT6TWM2OD16INMxJFYhdk1? Mn6zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MCF7-TamR7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDGO|IhcA>? MkTtTWM2OD16INMxJFMhdk1? M2rPZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS3TJlOPzJiaB?= NYW1TWJ2UUN3ME2xOUDDuSB4IH7N Mln6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MCF7-TamC3 NVfWb2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7CTJE4OiCq MW\JR|UxRTZiwsGgN{BvVQ>? MoK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MCF7-TamC6 NFvz[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu1O|IhcA>? NUX0RVE1UUN3ME22JOKyKDBwMTDuUS=> NWPRW3Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP1O|IhcA>? NETBNoFKSzVyPUWgxtEhOSCwTR?= M37tTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
SK-BR-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf0dWl[PzJiaB?= NVHMNVR3UUN3ME23JOKyKDBwMzDuUS=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
Eca109 NInoe3FHfW6ldHnvckBCe3OjeR?= NUjFUpdLOS13MDDuUS=> M1TZbVQ5KGh? M{LCfGROW09? NH76dnB{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4H5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
TE13 NVmxfZlXTnWwY4Tpc44hSXO|YYm= NIrDXJUyNTVyIH7N NVv6blc2PDhiaB?= Mn7qSG1UVw>? MXnzeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHrSdWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM6PSd-MkWxN|k{QTV:L3G+
Eca109 NVTReYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXtPYs4OC1zMECgcm0> NXrtU5lROjRxNEigbC=> MVXEUXNQ M1\kb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3PrR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
TE13 NESybmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMVExOCCwTR?= MYCyOE81QCCq NILOeINFVVOR NV;ifmRD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
MT-3 MYfLbY5ie2ViQYPzZZk> NFjQPIw4OiCq NFjO[ndFVVOR MX7JR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> MmL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MDA-MB-468 NH3JdpNMcW6jc3WgRZN{[Xl? M4\1[FczKGh? NHzPNYlFVVOR MnLYTWM2OD1yLkGxJOKyKDBwMEGgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NV:5PYt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
SUM-159 MXXLbY5ie2ViQYPzZZk> NVjUfYs{PzJiaB?= MonUSG1UVw>? MlS0TWM2OD1zLkeyJOKyKDBwM{Ogcm0h\m:{IFTSOEBmgHC{ZYPzbY9v MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MT-3 MoO0T4lv[XOnIFHzd4F6 MYO3NkBp MWTEUXNQ MUXJR|UxRTV2LkGxJOKyKDRwM{Kgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NVyyZo9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MDA-MB-468 MnO0T4lv[XOnIFHzd4F6 NWPWZXRYPzJiaB?= MnzLSG1UVw>? NFmwPGhKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? M3z1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
SUM-159 NV7BPJI{U2mwYYPlJGF{e2G7 NWC0W2VNPzJiaB?= NWjaUpFxTE2VTx?= MUnJR|UxRTZ7LkSgxtEhPC5{MzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NVLtRlVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MT-3 + NAC NW\IfJByU2mwYYPlJGF{e2G7 MYi3NkBp NYK2cnFMTE2VTx?= M1K3TGlEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? M1rPcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MT-3 + SB203580 M3vsTWtqdmG|ZTDBd5NigQ>? NYTQTWZ4PzJiaB?= NFTVOoFFVVOR NYnNN2pVUUN3ME2zPE41OSEEsTC1MlAzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= NVTSSHJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
DB NHjld5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjjdWtPOTBibl2= NWTsPIpUOjRiaB?= MmD0SG1UVw>? NH\tbolqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> M2fKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
SU-DHL-8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz6NVAhdk1? NUXLWJJSOjRiaB?= MmHlSG1UVw>? NHHBTI1qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> M4L3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
WSU-DLCL2 M1izXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrHcIsyOCCwTR?= NVqxbFVrOjRiaB?= NH3LfmdFVVOR M4X0colvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
ACC-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHNNE0yODBibl2= M{X2eVI1KGh? NVvEbm9{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVyxSJliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
ACC-2 M{i3R2Fxd3C2b4Ppd{BCe3OjeR?= NHnR[5IxNTJyIH7N MmfyNlQhcA>? NWHw[2dScW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2SyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{ewPVk2Lz5{NEO3NFk6PTxxYU6=
ACC-2 MVLGeY5kfGmxbjDBd5NigQ>? NGWxWm8xNTJyIH7N MX[yOEBp MkHKbY5kemWjc3XzJJRp\SClb372[ZJ{cW:wIH;mJGxEO0lidH:gUGM{UUl? NVvsfG1GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
BFTC905 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrQXIRROC1zMECwJI5O NFLh[mM1QCCqwrC= MkjsSG1UVw>? NWLCSpBiUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3i4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
T24 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqyNE0yODByIH7N M2TS[FQ5KGkEoB?= M37DRmROW09? MnGwTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVLBTpJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
TSGH8301  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\pNE0yODByIH7N M2OwTlQ5KGkEoB?= MorrSG1UVw>? NHvUNFBKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUPKOWpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
BFTC909 NH24TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLFbYcxNTFyMECgcm0> NW\IfodmPDhiaNMg NEnUeHhFVVOR NWrIcYV4UUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIe3OXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905 NH3PPXlCeG:ydH;zbZMhSXO|YYm= MV:yNEBvVQ>? MorLOFghcA>? Mm[xSG1UVw>? MoHsbY5lfWOnczDhdI9xfG:|aYO= MlXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
BFTC905 MV;GeY5kfGmxbjDBd5NigQ>? MYiyNEBvVQ>? M1i1b|Q5KGh? NELxWIdFVVOR MWXk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{Si2LSR?= MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
A2780p NUTFT21yTnWwY4Tpc44hSXO|YYm= NHK5dVUxNTFyMDDuUS=> NUfqcnJuOjRiaB?= MV\EUXNQ M1O4eYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= Ml7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NkK4O|UoRjJ2Mk[yPFc2RC:jPh?=
A2780cis NWrTbFN5TnWwY4Tpc44hSXO|YYm= M{n4b|AuOTByIH7N MWCyOEBp MnSySG1UVw>? MUTpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? M3HuSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[yPFc2Lz5{NEK2Nlg4PTxxYU6=
A2780p Mo\MRZBweHSxc3nzJGF{e2G7 NYW1b2tMPS1zMECgcm0> NH\iTI4zPC92ODDo M2j1SmROW09? MkTibY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NGDBU4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780cis NYmxOVFZSXCxcITvd4l{KEG|c3H5 NHiwOFc2NTFyMDDuUS=> NX3hXFVsOjRxNEigbC=> NH\EPIpFVVOR NVvjcVBTcW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NX;QZoZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlI5PzVpPkK0NlYzQDd3PD;hQi=>
SH-SY5Y M1PDe2Fxd3C2b4Ppd{BCe3OjeR?= M4\IW|EwOTBxMUCwJOK2VQ>? NGTQR4U4OiCq MX;EUXNQ NV7YNpBrcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3NEW2NEc,OjR{NUS1OlA9N2F-
HL-60 MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrJb3lYPzMEoHi= NV3ucZc3TE2VTx?= Moq2TWM2OD1yLkOgcm0> M4DST|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
U937  NHTUR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPudoFXPzMEoHi= NYKxNlJ3TE2VTx?= NGnuRlBKSzVyPUCuPEBvVQ>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
HL-60  M2nVXWZ2dmO2aX;uJGF{e2G7 M4qyb|HDqM7:TR?= M2nv[|YwOTJxMkSgbC=> M2K5eGROW09? M1G3RolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
U937  NV\xcWh7TnWwY4Tpc44hSXO|YYm= NV;sdZdEOcLizszN MWW2M|EzNzJ2IHi= Mkm3SG1UVw>? Mn\ibY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6= NXr1WWpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVg5PjJpPkKzOlE5QDZ{PD;hQi=>
HL-60 M4nMPWFxd3C2b4Ppd{BCe3OjeR?= MX:wMlEwOSEQvF2= MknNPEBp MoD4SG1UVw>? NULXUZBLcW6mdXPld{BieG:ydH;zbZM> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
Sk-NEP-1  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTSXmwyNTFyMECwJI5O NXrEbZBMOjRiaB?= MXHEUXNQ Ml\vTWM2OD1zMECgcm0> MnXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nke2PVkoRjJ|Mk[3Olk6RC:jPh?=
SK-NEP-1  MXfBdI9xfG:|aYOgRZN{[Xl? NX7WXZBNPTBxMUCwJI5O MVWxNk8zPCCq MnHNSG1UVw>? M4PyUolv\HWlZYOgZZBweHSxc3nz NIL3Rmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2O|Y6QSd-MkOyOlc3QTl:L3G+
TC-32 M2DpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfJNE4yNTFyMECgcm0> M2\1VWVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M33qOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
TC-71 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGwXWwxNjFvMUCwNEBvVQ>? MnrpSWM2OD13Lkegcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3TsOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
SK-ES-1 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fVelAvOS1zMECwJI5O NYDNVGI6TUN3ME2yMlghdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
RD-ES M3TsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[4ZVAvOS1zMECwJI5O M{GzOWVEPTB;Nj6yJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NULqbXd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OlE4PjNpPkKyPVYyPzZ|PD;hQi=>
HEK293 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfKNE4yNTFyMECgcm0> MoPCSWM2OD1{Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1OwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
M059J MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMVUxKG6P M1HhSFQ5KGh? NEXVVGhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHfNdY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059K NELUSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[wMVUxKG6P M2WwVVQ5KGh? NYrYWHhIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
M059J NWDjO|JKSXCxcITvd4l{KEG|c3H5 NV3VNm97OzBibl2= M1zWR|I1KGh? NFntPGRqdmS3Y3XzJIFxd3C2b4Ppdy=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
M059K MmDXRZBweHSxc3nzJGF{e2G7 MorCN|Ahdk1? NWf4T3JJOjRiaB?= Moi3bY5lfWOnczDhdI9xfG:|aYO= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
PANC-1 M1LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMlAyNTFyMECgcm0> NGr5[WE1QCCq NHziS3FKSzVyPUOuOlkhdk1? NXnxOJIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
MIAPaCa-2 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvkdmo{OC5yMT2xNFAxKG6P NIjDNoE1QCCq NXzvSpBZUUN3ME2yPU4{PiCwTR?= NV\Rb5hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
BxPC-3 NUTQfVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjxTnlkOC5yMT2xNFAxKG6P MojROFghcA>? MV;JR|UxRTNyLkK2JI5O MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
PANC-1 NHPOZYxHfW6ldHnvckBCe3OjeR?= M1P0[|AuOTByMDDuUS=> NInGOnYzPCCq MmfmbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
MIAPaCa-2 NHPpeWFHfW6ldHnvckBCe3OjeR?= NYjwUmdYOC1zMECwJI5O M1vhU|I1KGh? NHrZb|BqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NHfkUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
BxPC-3 M4Hs[2Z2dmO2aX;uJGF{e2G7 NGXGZVQxNTFyMECgcm0> M1fNNlI1KGh? M3zFTIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> M2HuW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN|g4OTxxYU6=
RPMI-7951 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILEVVdIUTVyPUOuNkBvVQ>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
SK-MEL-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf6d|FIUTVyPUSuNkBvVQ>? NFjaTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
A375 M3myTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW2[VIyT0l3ME22MlMhdk1? Mly5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
SK-MEL-28 M3Ho[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jabmdKPTB;Nz62JI5O NFXz[WQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
SK-MEL-2 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXEN4JIUTVyPUGxJI5O NUKx[IlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
DB NHPtcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\FdVQ5yqCq M1rHN2dKPTB;Mz61JI5O MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
Pfeiffer MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPrenA1QMLiaB?= MXPHTVUxRTNwOTDuUS=> NF2yNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO|UxQCd-MkGyN|c2ODh:L3G+
SU-DHL-5 NHfPephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWxO4o1QMLiaB?= NXvtc2RvT0l3ME2wMlI{KG6P MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
SU-DHL-8 NX2zVJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\oR5Q1QMLiaB?= MXzHTVUxRTFwNDDuUS=> M171flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
WSU-DLCL-2 NGLEXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fMclQ5yqCq NV\wZpB3T0l3ME2xMlQhdk1? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
A549 NHq0RZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mli5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlAyOzUQvF2= NGrS[3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEixOFM4PCd-Mki4NVQ{PzR:L3G+
DU145 MnLBR5l1d3SxeHnjbZR6KGG|c3H5 MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVA:OC5yMUO4{txO NULiNoR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
PC3 NHjFOGpEgXSxdH;4bYNqfHliYYPzZZk> NH7OWFBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliTWTUJIF{e2G7LDDFR|UxRTBwMEmy{txO NViyU|BqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
A549 NX:5VYJVTnWwY4Tpc44h[XO|YYm= MXTJcohq[mm2aX;uJI9nKFCDS{GgbY4hcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlXPxE1? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO|Q9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID